Results 171 to 180 of about 54,010 (241)

Comparative Efficacy of Fosnetupitant and Fosaprepitant for Delayed Vomiting in Patients Receiving Irinotecan-Oxaliplatin Combination Chemotherapy: A Retrospective Propensity Score-Matched Study. [PDF]

Cancer Manag Res
Maeda K, Kawada K, Hayashi T, Koyama S, Ishida T, Yoshioka T, Fukuda H, Horikawa I, Aizawa F, Niimura T, Yagi K, Goda M, Izawa-Ishizawa Y, Ishizawa K.   +13 more
europepmc   +1 more source

Phase II study of FOLFIRI with low-dose irinotecan plus ramucirumab as second-line treatment in Japanese patients with metastatic colorectal cancer (study rindo). [PDF]

Jpn J Clin Oncol
Hattori N, Nakayama G, Umeda S, Kishida T, Takeda S, Ezaka K, Tsutsuyama M, Sakai M, Hattori M, Ito T, Kanda M, Tanaka C, Murotani K, Ando M, Kodera Y.   +14 more
europepmc   +1 more source

Treatment patterns and clinical outcomes of metastatic gastric cancer in South Korea: real-world evidence from retrospective electronic medical records data. [PDF]

BMC Cancer
Kim E, Shin JY, Park S, Yoo JH, Kwon WS, Lee CK, Jung M, Kim HS, Chung HC, Rha SY.   +9 more
europepmc   +1 more source

The WEE1 inhibitor azenosertib broadly enhances efficacy of antibody-drug conjugates with topoisomerase I and microtubule inhibitor payloads. [PDF]

iScience
Guo X, Kim D, Harismendy O, Cabrera E, Chung H, Meric-Bernstam F, Lackner MR, Lee C, Ma J.   +8 more
europepmc   +1 more source

Long-Term Disease-Free Survival After Systemic-First Sequential Multimodal Therapy for Advanced and Recurrent Large-Cell Neuroendocrine Carcinoma of the Uterine Cervix: A Case Report. [PDF]

J Obstet Gynaecol Res
Wakana K, Akita M, Tsubata F, Kori Y, Odai T, Miyasaka N.   +5 more
europepmc   +1 more source

Evaluation of the efficacy and tolerability of bevacizumab-based treatments in recurrent primary brain tumors: a multicenter real-world Turkish Oncology Group (TOG) study. [PDF]

BMC Cancer
Sucuoğlu İşleyen Z, Seçmeler Ş, Sakin A, Cihan Ş, Beşiroğlu M, Kahraman S, Karakurt Eryılmaz M, Zeynelgil E, Çalışkan Yıldırım E, Kut E, Şengül N, Paksoy Türköz F, Alan Ö, Özkul Ö, Işık S, Yılmaz F, Gülmez A, Türker S, Karakaya G, Günaldı M, Özer L, Aksoy A, Karataş F, Sakalar T, Demirtaş Esmer D, Teker F, Demir N, Dülgar Ö, Turhal S, Türk HM, Ertürk K, Çelik E, Atcı MM.   +32 more
europepmc   +1 more source

Metabolomic Study of 7-Ethyl-9-(<i>N</i>-methyl)aminomethyl-10-hydroxycamptothecin Derivative (NMe)-The Chemotherapeutic Drug Candidate Versus Irinotecan (IR) on a Mouse Model. [PDF]

Metabolites
Surynt P, Naumczuk B, Popławska M, Urbanowicz M, Unrug-Bielawska K, Cybulska-Lubak M, Sadowska-Markiewicz Z, Sitkowski J, Bednarek E, Zeber-Lubecka N, Kozerski L, Mikula M, Ostrowski J.   +12 more
europepmc   +1 more source

Efficacy and Safety Assessment of 5-Fluorouracil, Irinotecan and Oxaliplatin-Loaded Implants in Mouse and Pig Models for Pancreatic Cancer Therapy. [PDF]

Adv Mater
Wade SJ, Kumar AA, Nitschke SO, Joyce P, Minaei E, Reuter SE, Penney C, Warren H, Shepherd R, Dinoro JN, Wallace GG, Dosseto A, Ansar S, Islam N, Lochhead A, Sharbeen G, Phillips PA, Aghmesheh M, Hawthorne WJ, Vine-Perrow KL.   +19 more
europepmc   +1 more source

Colorectal Cancer Organoid Model Reveals the Mechanisms of Irinotecan Resistance at Single-Cell Resolution. [PDF]

Cancer Med
Pan Y, Chen L, Hu Y, Chang J, Xu X, Xu S, Li Y, Du J, Wang J, Xu W.   +9 more
europepmc   +1 more source

Bevacizumab-Based Therapy Is Associated with Prolonged Progression-Free Survival in Patients with Peritoneal Mucinous Metastatic Colorectal Cancer. [PDF]

J Clin Med
Can S, Çakıcı V, Kahveci GB, Eroğlu Ş, Tok B, Uygun G, Özer E, Çırak Y, Gökmen İ.   +8 more
europepmc   +1 more source